GleamWall
中文EN

CHRS Coherus Oncology, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1512762 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY44.4%
TTM net income YoY-187.7%
TTM EPS YoY-175.2%
Revenue 3-yr CAGR-36.7%
Net income 3-yr CAGR—

Margins

Gross margin69.8%
Operating margin-275.9%
Net margin-253.4%
FCF margin—
EBITDA margin-274.3%

Returns

ROE-240.5%
ROA-39.5%
ROIC (approx.)—
Asset turnover0.16x

Leverage & solvency

Liabilities / assets85.2%
Debt / equity0.00x
Current ratio1.51x
Interest coverage-15.52x

Cash quality & payout

Operating cash flow / net income1.28x
Accruals ratio11.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$14.27M$14.31M$12.31M$12.75M$11.57M$10.25M$7.60M$7.73M
Cost of revenue$4.09M$4.24M$3.81M$4.04M$3.72M$3.40M$2.65M$2.75M
Gross profit$10.18M$10.06M$8.50M$8.70M$7.85M$6.86M$4.95M$4.98M
R&D expense$22.61M$21.44M$21.54M$30.97M$27.25M$26.31M$24.36M$20.76M
SG&A expense$21.23M$20.95M$23.10M$23.61M$24.93M$26.04M$26.02M$29.61M
Operating income-$33.65M-$32.33M-$36.15M-$45.88M-$44.33M-$45.49M-$45.44M-$45.38M
Interest expense$2.78M$2.32M$2.19M$2.25M$2.33M$2.28M$2.15M$1.91M
Pretax income-$38.88M-$33.35M-$36.94M-$46.35M-$44.52M-$44.86M-$47.40M-$46.09M
Net income-$39.33M-$20.63M-$38.33M-$37.64M-$35.53M$297.77M-$56.57M-$50.70M
EBITDA-$32.80M-$31.47M-$35.27M-$47.61M-$44.03M-$45.19M-$44.39M-$45.28M
EPS (basic)-0.25-0.13-0.28—-0.312.57-0.49—
EPS (diluted)-0.25-0.13-0.28—-0.312.572.57—
Weighted avg. shares (diluted)154.97M154.82M136.40M—116.23M116.08M116.08M—
Balance sheet
Cash & equivalents$53.49M$82.92M$115.24M$88.88M$103.59M$217.16M$82.67M$126.25M
Short-term investments$30.14M$22.38M$51.81M$83.25M$88.31M$20.74M——
Receivables$13.72M$13.88M$22.06M$17.82M$9.24M$5.11M$60.49M$111.32M
Inventory$4.82M$5.67M$4.83M$3.17M$2.05M$4.51M$3.52M$4.21M
Current assets$114.13M$133.79M$206.03M$206.71M$460.95M$380.20M$310.18M$341.58M
PP&E, net$652,000$865,000$1.09M$1.34M$1.63M$1.91M$2.26M$2.58M
Intangibles$18.12M$18.75M$19.38M$20.00M$20.62M$23.45M$24.12M$24.79M
Total assets$171.10M$191.18M$266.02M$258.34M$516.52M$439.46M$371.07M$448.53M
Current liabilities$75.64M$75.51M$132.33M$140.39M$372.30M$263.63M$255.04M$282.98M
Total liabilities$145.85M$130.34M$187.40M$197.33M$428.75M$319.64M$554.54M$580.52M
Shareholders' equity$25.25M$60.84M$78.62M$61.01M$87.77M$119.83M-$183.47M-$131.99M
Shares outstanding154.53M154.47M154.22M121.15M116.24M116.22M115.91M115.61M
Cash flow statement
Operating cash flow-$34.02M-$62.09M-$57.89M-$19.72M-$46.34M-$46.63M-$25.83M$28.61M
Investing cash flow-$7.61M$29.63M$30.66M-$2.84M-$67.23M$462.64M-$17.49M-$542,000
Financing cash flow$12.05M$144,000$53.59M$8.08M$2,000-$281.52M-$264,000$231,000
Depreciation & amortization$853,000$862,000$881,000-$1.73M$300,000$300,000$1.05M$100,000
Stock-based compensation$3.68M$2.58M$2.38M$2.78M$3.39M$5.42M$5.37M$6.38M

Free plan shows the latest 8 periods; Pro shows all 55 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.